STROKOG: A Consortium of Studies of Post-Stroke Cognitive Decline and Dementia

Organizer: Perminder Sachdev
Chair: Christopher Chen (on behalf of Perminder Sachdev)

Presentations by Darren Lipnicki and study representatives

1. Why a Consortium?
2. Proposed Structure of the Consortium
3. Participating Studies
   a. Each Study Representative  *See Table Below
   b. Studies Not Represented at VASCOG
4. Data Platform
5. Issues Regarding Harmonization and Analysis
6. Discussion
7. Nomination of Scientific Board
8. Specific Projects – Data-Based
9. Position Statements; Concept Papers

Participating Studies:

<table>
<thead>
<tr>
<th>Study</th>
<th>Organizer/Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Biological and Pharmacological Factors Influencing Stroke Outcome (BIOSTROKE)</td>
<td>Charlotte Cordonnier</td>
</tr>
<tr>
<td>Cognition and Affect after Stroke: Prospective Evaluation of Risks (CASPER)</td>
<td>Syenna Schievink</td>
</tr>
<tr>
<td>Cognition and Neocortical Volume After Stroke (CANVAS) Study</td>
<td>Amy Brodtmann</td>
</tr>
<tr>
<td>Cognitive Function After Stroke (CogFAST)</td>
<td>Raj Kalaria</td>
</tr>
<tr>
<td>Cognitive Function After Stroke (CogFAST) Nigeria Study</td>
<td>Rufus Akinyemi (presenter)</td>
</tr>
<tr>
<td>Cognitive Function After Stroke (CogFAST) Nigeria Study</td>
<td>Raj Kalaria</td>
</tr>
<tr>
<td>Cognitive Outcome After Stroke (COAST)</td>
<td>Catherine Dong</td>
</tr>
<tr>
<td>Determinants of Dementia After Stroke (DEDEMAS)</td>
<td>Marco Düring</td>
</tr>
<tr>
<td>Lille Stroke/Dementia</td>
<td>Charlotte Cordonnier</td>
</tr>
<tr>
<td>Maastricht Cognitive Disorders After Stroke (CODAS)</td>
<td>Syenna Schievink</td>
</tr>
<tr>
<td>Multicenter Prospective Stroke Cohort in Korea</td>
<td>Byung-Chul Lee</td>
</tr>
<tr>
<td></td>
<td>Hee-Joon Bae</td>
</tr>
<tr>
<td></td>
<td>Kyung-Ho Yu</td>
</tr>
<tr>
<td>North East Melbourne Stroke Incidence Study (NEMESIS)</td>
<td>Velandai Srikanth</td>
</tr>
<tr>
<td>Prognosis of Intracerebral Haemorrhage (PITCH)</td>
<td>Charlotte Cordonnier</td>
</tr>
<tr>
<td>Single Center Prospective VCI Cohort in Korea</td>
<td>Jae-Sung Lim (presenter)</td>
</tr>
<tr>
<td></td>
<td>Hee-Joon Bae</td>
</tr>
<tr>
<td>Stroke Registry Investigating Cognitive Decline (STRIDE)</td>
<td>Bonnie Lam</td>
</tr>
<tr>
<td>Study of Factors Influencing Post–Stroke Dementia (STROKDEM)</td>
<td>Charlotte Cordonnier</td>
</tr>
<tr>
<td>Sydney Stroke Study (SSS)</td>
<td>Perminder Sachdev</td>
</tr>
</tbody>
</table>
1. **Brain Areas for Diagnosing VCI**  
   Raj Kalaria (Newcastle University, UK)

2. **Animal Model of VCI**  
   Masafumi Ihara (Department of Stroke and Cerebrovascular Diseases, National Cerebral and Cardiovascular Center, Japan)

3. **VRFs & Cognitive Decline**  
   Florence Pasquier (Université Lille Nord de France, France)

4. **Burgeoning of Dementia Concepts**  
   Toshiya Fukui (Neurology, Kawasaki Memorial Hospital, Japan / Department of Neurology, Showa University, Japan)
September 17 (Thu.)  8:15 - 8:30  Room A1 (TFT Hall 1000)
Opening Ceremony

September 17 (Thu.)  8:30 - 10:00  Room A1 (TFT Hall 1000)

Theme 1: Diagnosing Vascular Cognitive Disorders
Chairs: Mikio Shoji (Hirosaki University, Japan)
Sandra E. Black (Sunnybrook Health Sciences Centre, Canada)

T1-1  Diagnosing Vascular Cognitive Disorders (VCD): Are Imaging Markers Changing the Game?
Sandra E. Black (Sunnybrook Health Sciences Centre, University of Toronto, Canada)

T1-2  What is the Prevalence of Poststroke Cognitive Impairment in Hospitalized Cohorts?
A Meta-analysis and First Results from the French VCI Harmonization Standards (VCIHS) Study Group.
Olivier Godefroy (Department of Neurology and Functional Neuroscience Lab, Amiens University Hospital, France)

T1-3  Biomarkers of Vascular Dementia
Mikio Shoji (Department of Neurology, Hirosaki University, Japan)

T1-4  VCI and VaD Case Finding by the Latent Variable ‘δ’
Donald R. Royall (Department of Psychiatry, University of Texas Health Science Center at San Antonio, USA / Department of Medicine, University of Texas Health Science Center at San Antonio, USA / Department of Family & Community Medicine, University of Texas Health Science Center at San Antonio, USA)

T1-5  Relationships Between Brain B-Amyloid, Cerebrovascular Disease, and Cognition
William Jagust (Helen Wills Neuroscience Institute, University of California, Berkeley, USA)

September 17 (Thu.)  10:30 - 12:00  Room A1 (TFT Hall 1000)

Theme 2: Small Vessel Disease and Dementia
Chairs: Ken Nagata (Research Institute for Brain and Blood Vessels, Japan)
Geert Jan Biessels (Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, The Netherlands)

T2-1  Small Vessel Disease under the Magnifying Glass: High Resolution Imaging with 7T MRI
Geert Jan Biessels (Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, The Netherlands)

T2-2  Risk Factors for Recurrent Subcortical Small-vessel Lesions
Ken Nagata (Department of Neurology, Research Institute for Brain and Blood Vessels, Japan)

T2-3  Brain Network Disruption and Cognitive Impairment in Aging and Dementia
Shuhei Yamaguchi (Department of Neurology, Shimane University, Japan)

T2-4  Cerebral Amyloid Angiopathy in Alzheimer’s Disease
Masahito Yamada (Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Japan)

T2-5  Post-stroke Cognitive Impairment and Dementia
Toru Yamashita (Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan)

T2-6  Predictors of Delayed-onset Dementia after Stroke/Transient Ischemic Attack: STRoke Registry Investigating Cognitive DEcline (STRIDE) Study
Bonnie Yin Ka Lam (Department of Medicine and Therapeutics, Chinese University of Hong Kong, China)
# VAS-COG World 2015

**7th World Congress of the International Society for Vascular Behavioural and Cognitive Disorders**

## September 16-19, 2015
Tokyo Fashion Town, Tokyo, Japan

### VAS-COG World 2015

#### September 17 (Thu.) 12:10 - 13:10 Room A1 (TFT Hall 1000)

**Luncheon Seminar 1**

Chair: Katsuya Urakami (Department of Biological Regulation, Faculty of Medicine, Tottori University, Japan)

**LS1**

**Vascular Factors in Alzheimer’s Disease**

Koji Abe (Department of Neurology and Okayama University School of Medicine, Japan)

Sponsored by: Eisai Co., Ltd.

#### September 17 (Thu.) 12:10 - 13:10 Room B (TFT Hall 300)

**Luncheon Seminar 2**

Chair: Masahito Yamada (Department of Neurology & Neurobiology of Aging Kanazawa University Graduate School of Medical Sciences, Japan)

**LS2**

**Vascular Risks and Cognitive Reserve in Alzheimer’s Disease**

Ken Nagata (Research Institute for Brain and Blood Vessels Akita, Japan)

Sponsored by: Takeda Pharmaceutical Company Limited
Janssen Pharmaceutical K.K.

#### September 17 (Thu.) 13:15 - 14:30 Room A2 (TFT Hall 1000)

**Poster Viewing and Discussion 1 - 14**

13:15 - 13:45 Poster Viewing (free discussion)
13:45 - 14:30 Poster Tour (7min. per person)

*See Poster Program (P.22 - ) for details.*

#### September 17 (Thu.) 14:30 - 15:30 Room A1 (TFT Hall 1000)

**Poster Review Session 1**

*See Poster Program (P.22 - ) for details.*

#### September 17 (Thu.) 16:00 - 17:00 Room A1 (TFT Hall 1000)

**Debate 1: Do Vascular Risk Factors Make a Major Contribution to the Etiology of AD ?**

Chairs: Issei Komuro (The University of Tokyo, Japan)
Raj N. Kalaria (Newcastle University, UK)

**D1-1**

**Alzheimer’s Disease is a Vascular Dementia**

Deborah Gustafson (State University of New York-Downstate Medical Center, Department of Neurology in Brooklyn Affiliate Researcher/Docent, Neuropsychiatric Epidemiology Unit, Sahlgrenska Academy, University of Gothenburg, Sweden)

**D1-2**

**Vascular Risk Factors Share the Risk of Alzheimer’s Disease**

Koji Abe (Department of Neurology, Okayama University, Japan)

**D1-3**

**Atrial Fibrillation and Cognitive Decline**

Shinichiro Uchiyama (Clinical Research Center for Medicine, International University of Health and Welfare / Center for Brain and Cerebral Vessels, Sanno Hospital and Sanno Medical Center, Japan)

**D1-4**

**Lower Cerebral Blood Flow is Associated with Cognitive Decline in Patients with Alzheimer’s Disease**

Marije R. Benedictus (Alzheimer Center and Neurology, VU University Medical Center, The Netherlands)
September 17 (Thu.) 17:00 - 18:00 Room A1 (TFT Hall 1000)

YI Meeting 1: Dementia and Vascular Risk Factors (VRFs)

Chairs: Mohammad Arfan Ikram (Erasmus University Medical Center, The Netherlands)
Toru Yamashita (Department of Neurology, Okayama University, Japan)

YI1-1 Cognitive and Affective Functions in Diabetic Patients Associated with Diabetes-related Factors, White Matter Abnormality, and Aging
Nozomi Hishikawa (Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan)

YI1-2 Aβ Immunotherapy for Alzheimer’s Disease: Effects on Apolipoprotein E and Cerebral Vasculature
Kenji Sakai (Department of Neurology, Kanazawa University Hospital, Japan / Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, UK)

YI1-3 The Elimination of Amyloid β from the Brain: Implications for the Pathogenesis of Alzheimer’s Disease
Alan William Joe Morris (Clinical Neurosciences, Faculty of Medicine, University of Southampton, UK)

YI1-4 Stroke and Dementia: Methodological Considerations to Study Multi-factorial Diseases
Mohammad Arfan Ikram (Erasmus University Medical Center, The Netherlands)

September 17 (Thu.) 18:00 - 19:00 Room A1 (TFT Hall 1000)

Evening Seminar 1

Chair: Toshiki Mizuno (Department of Neurology, Kyoto Prefectural University of Medicine, Japan)

ES1 Are there any racial differences of clinical benefits among DOACs?
Takehiko Nagao (Department of Neurology Nippon Medical School Tama-Nagayama Hospital, Japan)

Sponsored by: DAIICHI SANKYO CO., Ltd.

September 17 (Thu.) 18:00 - 19:00 Room B (TFT Hall 300)

Evening Seminar 2

Chair: Yasuo Terayama (Division of Neurology and Gerontology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Japan)

ES2 Recent Advances and Topics in Anticoagulant Therapy in Patients with Atrial Fibrillation
Shinichiro Uchiyama (Clinical Research Center for Medicine, International University of Health and Welfare Center for Brain and Cerebral Vessels, Sanno Hospital and Sanno Medical Center, Japan)

Sponsored by: Bristol-Myers Squibb
### Theme 3: Vascular Factors in AD and Other Dementia

**September 18 (Fri.) 8:30 - 10:00 Room A1 (TFT Hall 1000)**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>T3-1</td>
<td>Impact of Vacular Risk Factors (VRF) in Alzheimer’s Disease (AD)</td>
<td>Koji Abe (Department of Neurology, Okayama University, Japan)</td>
</tr>
<tr>
<td>T3-2</td>
<td>The Failure of Perivascular Clearance Along Cerebral Arterial Walls and the Pathogenesis of Alzheimer’s Disease</td>
<td>Roxana O Carare (University of Southampton, UK)</td>
</tr>
<tr>
<td>T3-3</td>
<td>Roles of Protective Arm of Renin Angiotensin System in Vascular Remodeling</td>
<td>Masatosu Horii (Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Japan)</td>
</tr>
<tr>
<td>T3-4</td>
<td>Microbleeds in Dementia with Lewy Bodies: Prevalence and Clinical Implications</td>
<td>Toshiya Fukui (Neurology, Kawasaki Memorial Hospital, Japan)</td>
</tr>
<tr>
<td>T3-5</td>
<td>The Pathological Interaction between Diabetes and Alzheimer’s Disease</td>
<td>Naoyuki Sato (Department of Clinical Gene Therapy, Department of Geriatric Medicine, Osaka University, Japan)</td>
</tr>
<tr>
<td>T3-6</td>
<td>Large and Small Vessel Disease - What is Most Likely Seen in AD and Other Dementia?</td>
<td>Elisabet Englund (Department of Pathology/Neuropathology, Division of Clinical Sciences, Lund University, Sweden)</td>
</tr>
</tbody>
</table>

### Theme 4: Post-stroke Dementia, CCA, and Risk Factors

**September 18 (Fri.) 10:30 - 12:00 Room A1 (TFT Hall 1000)**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>T4-1</td>
<td>High Incidence of Dementia Conversion than Stroke Recurrence in Post-stroke Patients of Late Elder Society</td>
<td>Yumiko Nakano (Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan)</td>
</tr>
<tr>
<td>T4-2</td>
<td>Chronic Kidney Disease and Dementia</td>
<td>Kazuo Kitagawa (Department of Neurology, Tokyo Women’s Medical University, Japan)</td>
</tr>
<tr>
<td>T4-3</td>
<td>Poststroke Dementia - STRIDE Study</td>
<td>Vincent C.T. Mok (Medicine and Therapeutics, The Chinese University of Hong Kong, China)</td>
</tr>
<tr>
<td>T4-4</td>
<td>Carotid Stenosis and Vascular Dementia</td>
<td>Tsong-Hai Lee (Stroke Section, Department of Neurology, Linkou Chang Gung Memorial Hospital, Taiwan)</td>
</tr>
<tr>
<td>T4-5</td>
<td>Diabetes Mellitus as a Risk Factor of Post-stroke Dementia</td>
<td>Yasuo Terayama (Division of Neurology and Gerontology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Japan)</td>
</tr>
<tr>
<td>T4-6</td>
<td>Clinical and Imaging Diversity of CAA</td>
<td>Yosuke Wakutani (Neurology, Medical Center for Neurocognitive Disorders, Kurashiki Heisei Hospital, Japan)</td>
</tr>
</tbody>
</table>
## September 18 (Fri.) 12:10 - 13:10 Room A1 (TFT Hall 1000)
### Luncheon Seminar 3
**Chair:** Yoshio Ikeda  
*Department of Neurology, Gunma University Graduate School of Medicine, Japan*

**LS3**  
**APHASIOLOGY IN DEMENTIA**  
**~CLINICAL FEATURES AND POSSIBLE TREATMENT~**  
Toshiya Fukui  
*Kawasaki Memorial Hospital / Department of Neurology, Showa University, Japan*

*Sponsored by:*  
Janssen Pharmaceutical K.K.  
Takeda Pharmaceutical Company Limited

## September 18 (Fri.) 12:10 - 13:10 Room B (TFT Hall 300)
### Luncheon Seminar 4
**Chair:** Masatsugu Horiuchi  
*Department of Molecular Cardiovascular Biology and Pharmacology Ehime University Graduate School of Medicine, Japan*

**LS4**  
**Optimal Medical Therapy for Recurrent Stroke**  
Yasuo Terayama  
*Division of Neurology and Gerontology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Japan*

*Sponsored by:*  
AstraZeneca K.K.

## September 18 (Fri.) 13:15 - 13:45 Room A1 (TFT Hall 1000)
### General Assembly

## September 18 (Fri.) 13:15 - 14:30 Room A2 (TFT Hall 1000)
### Poster Viewing and Discussion 15 - 28

**13:15 - 13:45**  
Poster Viewing (free discussion)  
Poster Tour (7min. per person)

*See Poster Program (P.22 - ) for details.

## September 18 (Fri.) 14:30 - 15:30 Room A1 (TFT Hall 1000)
### Poster Review Session 2

*See Poster Program (P.22 - ) for details.

## September 18 (Fri.) 16:00 - 17:00 Room A1 (TFT Hall 1000)
### Debate 2: Is It Possible to Prevent MCI from Converting into AD ?
**Chairs:**  
Elisabet Englund  
*Department of Pathology/Neuropathology, Division of Clinical Sciences, Lund University, Sweden*  
Shokei Mitsuyama  
*Faculty of Life Sciences Kumamoto University, Japan*

**D2-1**  
**Novel Treatments in Prevention of Dementia in Co-morbid Vascular and Amyloid Models**  
David Floyd Cechetto  
*Department of Anatomy & Cell Biology, University of Western Ontario, Canada*

**D2-2**  
**Early Detection and Dementia Prevention Classes for Community Dwelling Older Adults with MCI**  
Katsuya Urakami  
*Department of Biological Regulation, University of Tottori, Japan*

**D2-3**  
**Does Aβ-Immunotherapy Work ?**  
Etsuro Matsubara  
*Department of Neurology, Ota University Faculty of Medicine, Japan*

**D2-4**  
**Alzheimer’s Disease and Subcortical Vascular Disease in a Memory Clinic Setting; Report from the Gothenburg MCI Study**  
Anders Wallin  
*University of Gothenburg, Sweden*
### September 18 (Fri.) 17:00 - 18:00  Room A1 (TFT Hall 1000)

#### YI Meeting 2: Cerebrovascular Impact for AD

**Chairs:** Masafumi Ihara (Department of Stroke and Cerebrovascular Diseases, National Cerebral and Cardiovascular Center, Japan)  
Kaavya Narasimhalu (National Neuroscience Institute, SGH Campus, Singapore)

<table>
<thead>
<tr>
<th>YI2-1</th>
<th>Effects of Cerebrovascular Disease on the Neuropsychological Profile of AD, DLB, and FTLD – An Autopsy Study –</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hiroshi Yoshizawa (Department of Neurology, Tokyo Women’s Medical University, Japan)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>YI2-2</th>
<th>Bench to Bedside: Using Mouse Models of Chronic Cerebral Hypoperfusion to Identify New Treatment for Dementia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Masafumi Ihara (Department of Stroke and Cerebrovascular Diseases, National Cerebral and Cardiovascular Center, Japan)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>YI2-3</th>
<th>Inflammation and Post Stroke Cognitive Impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Kaavya Narasimhalu (National Neuroscience Institute, SGH Campus, Singapore / School of Public Health, National University of Singapore, Singapore / Department of Pharmacology, National University of Singapore, Singapore)</td>
</tr>
</tbody>
</table>

### September 18 (Fri.) 18:00 - 19:00  Room A1 (TFT Hall 1000)

#### Evening Seminar 3

**Chair:** Koji Abe (Department of Neurology and Neuroscience Okayama University School of Medicine, Dentistry and Pharmaceutical Sciences, Japan)

<table>
<thead>
<tr>
<th>ES3</th>
<th>The Strategic Stroke Prevention in the Era of Super-aged Society</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ken Nagata (Department of Neurology Research Institute for Brain and blood Vessels, Japan)</td>
</tr>
</tbody>
</table>

Sponsored by: Bayer Yakuhin, Ltd.
### Theme 5: Neuropsychiatric Diseases and Vascular Factors

**Room A1 (TFT Hall 1000)**

#### September 19 (Sat.) 8:30 - 10:00

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>T5-1</td>
<td>The Intriguing Interrelationship between Vascular Disease and Psychiatric Disorders</td>
<td>Ingmar Skoog (Neuropsychiatric Epidemiology Unit, Dept of Psychiatry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at Göteborg University, Sweden)</td>
</tr>
<tr>
<td>T5-2</td>
<td>Vascular and Inflammatory Changes in Depression</td>
<td>John O’Brien (Department of Psychiatry, University of Cambridge, UK)</td>
</tr>
<tr>
<td>T5-3</td>
<td>Glucose Metabolism in Dementia</td>
<td>Yoshio Ikeda (Department of Neurology, Gunma University Graduate School of Medicine, Japan)</td>
</tr>
<tr>
<td>T5-4</td>
<td>Vascular Factors in Poststroke Neuropsychiatric Disorders</td>
<td>Wai Kwong Tang (Department of Psychiatry, the Chinese University of Hong Kong, Hong Kong / CUHK Shenzhen Research Institute, China)</td>
</tr>
<tr>
<td>T5-5</td>
<td>Association of Small Vessel Disease with Neuropsychiatric Symptoms in Patients with Alzheimer’s Disease</td>
<td>Manabu Ikeda (Department of Neuropsychiatry, Faculty of Life Sciences, Kumamoto University, Japan)</td>
</tr>
<tr>
<td>T5-6</td>
<td>Unexpected Early Changes in Cerebrovascular Integrity in Mouse Hippocampus after Bilateral Carotid Artery Stenosis</td>
<td>Gregory Bix (Department of Neurology, Anatomy &amp; Neurobiology and Sanders-Brown Center on Aging, University of Kentucky, USA)</td>
</tr>
</tbody>
</table>

### Theme 6: Emerging Neuroimaging & Biomarker for Dementia

**Room A1 (TFT Hall 1000)**

#### September 19 (Sat.) 10:30 - 12:00

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>T6-1</td>
<td>Assessing Cerebral Microinfarcts with High-resolution MRI in Aging and Dementia</td>
<td>Susanne Janneke van Veluw (Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, The Netherlands)</td>
</tr>
<tr>
<td>T6-2</td>
<td>Retinal Microvascular Network and Retinal Ganglion Cell Imaging in Dementia</td>
<td>Carol Y. Cheung (Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong)</td>
</tr>
<tr>
<td>T6-3</td>
<td>Lipid Biomarkers for Subcortical Ischemic Vascular Dementia, Alzheimer’s Disease and Mixed Dementia</td>
<td>Guanghou Shui (Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore)</td>
</tr>
<tr>
<td>T6-4</td>
<td>Identification of Diabetes-related Dementia; Neuroimaging Studies</td>
<td>Haruo Hanyu (Department of Geriatric Medicine, Tokyo Medical University, Japan)</td>
</tr>
<tr>
<td>T6-5</td>
<td>Novel Molecular Pathophysiology of Vascular Dementia Revealed by Profiling Plasma Samples and Postmortem Brain Tissues</td>
<td>Siu Kwan Sze (Nanyang Technological University, Singapore)</td>
</tr>
<tr>
<td>T6-6</td>
<td>White Matter Microstructure in Aging and Cognitive Decline</td>
<td>Meike Willemijn Vernooij (Department of Radiology and Epidemiology, Erasmus MC, The Netherlands)</td>
</tr>
</tbody>
</table>
Luncheon Seminar 5

Chair: Ryuichi Morishita (Department of Clinical Gene Therapy Graduate School of Medicine, Osaka University, Japan)

L55 Neuroprotective and Symptomatological action of memantine for Alzheimer disease
Shun Shimohama (Department of Neurology Sapporo Medical University, Japan)

Sponsored by: DAIICHI SANKYO CO., Ltd.

Chairman’s Conclusion and Adjourn